Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JP1302 是一种具有选择性的 α2C 肾上腺受体拮抗剂,其对人类 α2C 受体的 Kb 值为 16 nM,Ki 为 28 nM。JP1302 具有抗抑郁活性,可破坏 FACT 复合物并降解组蛋白H1,可用于研究神经精神障碍、急性肾功能衰竭和肾损伤。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 375 | 现货 | ||
5 mg | ¥ 830 | 现货 | ||
10 mg | ¥ 1,230 | 现货 | ||
25 mg | ¥ 2,320 | 现货 | ||
50 mg | ¥ 3,990 | 现货 | ||
100 mg | ¥ 5,680 | 现货 | ||
500 mg | ¥ 11,700 | 现货 |
产品描述 | JP1302 is a selective α2C adrenoceptor antagonist with a Kb value of 16 nM and a Ki of 28 nM for human α2C receptors.JP1302 has antidepressant activity, disrupts the FACT complex and degrades histone H1.JP1302 has been used in the study of neuropsychiatric disorders, acute renal failure, and renal injury. |
体外活性 | JP1302与α2A或α2B相比,展现出约100倍的更高亲和力。[1] |
体内活性 |
JP1302 (5 μmol/kg; once; Sprague-Dawley rats) is capable of complete reversal of the impairment in PPI induced in Sprague-Dawley rats by the psychotomimetic NMDA receptor antagonist, phencyclidine, and similar results are found in Wistar rats.[1] JP1302 (1-10 μmol/kg) decreases immobility time in the FST to a level similar to that seen with 10-30 μmol/kg of the antidepressant Desipramine.[1] JP1302 (3 mg/kg; IV, pre-treatment: administered 5 min before the induction of ischemia, post-treatment: injected 45 min after the initiation of reperfusion; once; Male Sprague Dawley rats ) significantly ameliorated renal dysfunction in the rats at 24 h after reperfusion. post-ischemic administration of JP-1302 significantly ameliorated renal dysfunction, and histological damage and reduced apoptotic cells and pro-inflammatory cytokine mRNA expression.[3] |
分子量 | 368.47 |
分子式 | C24H24N4 |
CAS No. | 80259-18-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 44.14 mg/mL
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
JP1302 80259-18-3 GPCR/G Protein Neuroscience Adrenergic Receptor JP-1302 JP 1302 dihydrochloride JP 1302 Inhibitor inhibitor inhibit